Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
21.00
+2.09 (11.02%)
At close: Oct 14, 2025, 4:00 PM EDT
20.83
-0.17 (-0.81%)
After-hours: Oct 14, 2025, 4:43 PM EDT
Spyre Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
65
Market Cap
1.27B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 886.00K | -1.44M | -61.96% |
| Dec 31, 2022 | 2.33M | -16.41M | -87.57% |
| Dec 31, 2021 | 18.74M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
SYRE News
- 20 hours ago - Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock - GlobeNewsWire
- 1 day ago - Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 9 days ago - Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 - GlobeNewsWire
- 25 days ago - Intelligent Development Could Make Spyre Therapeutics Best In Show - Seeking Alpha
- 5 weeks ago - Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum - GlobeNewsWire
- 5 weeks ago - Spyre Therapeutics Announces Grants of Inducement Awards - GlobeNewsWire
- 2 months ago - Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward - Seeking Alpha